LYR-220, Lyra’s second product candidate, is in Phase 2 development for the millions of chronic rhinosinusitis (CRS) patients who have undergone a prior sinus surgery but continue to have persistent disease.

Like LYR-210, LYR-220 is an anti-inflammatory implantable drug matrix designed to elute mometasone furoate consistently and locally for up to six months from a single administration to the inflamed mucosal tissue.

Designed for patients whose nasal cavity is enlarged due to sinus surgery, LYR-220 employs an oversized matrix. Surgical interventions do not address the underlying inflammation that is the hallmark of CRS and, as a result, symptoms often return within the first year following surgery in up to two-thirds of CRS patients.

LYR-220 is designed as a potential preferred alternative to revision sinus surgery and post-surgical medical management.

LYR-220 in BEACON Phase 2 Study
Brent A. Senior, MD, FACS, FARS
Chief, Division of Rhinology, Allergy, and Endoscopic Skull Base Surgery, UNC School of Medicine and BEACON Principal Investigator

LYR-220 placement compared to LYR-210

Back to Top